Source:http://linkedlifedata.com/resource/pubmed/id/11182049
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2001-2-22
|
pubmed:abstractText |
Therapeutic strategies for patients with advanced-stage adenocarcinoma of the breast frequently include the use of cytotoxic chemotherapy. Insulin-like growth factor I (IGF-I) receptor, a key factor in cell-cycle regulation, is frequently overexpressed in high-grade breast cancers. IGF-I receptor overexpression in these tumors may provide a target for novel molecular therapy against this disease. Early passage samples of estrogen-responsive (ER+) MCF 7 and estrogen receptor-negative (ER-) MDA-231 cells were cultured in semi-confluent conditions. Dose-titrations were performed for doxorubicin and taxol with receptor modulation using IGF-I or a competitive receptor inhibitor, alphaIR3. The addition of 100 ng/ml IGF-I resulted in a >2-fold mitogenic response in both ER+ and ER- cells. Receptor activation prior to the treatment with cytotoxic chemotherapeutic agents altered the pattern of response with a 26.3% increase in IC50. Doxorubicin and taxol both produced dose-related toxicity with IC50 of 0.05 microg/ml and 0.00 microg/ml respectively. The addition of alphaIR3 resulted in increased cytotoxicity in IGF-I stimulated cells compared with the use of doxorubicin or taxol alone. These results suggest that IGF-I receptor modulation alters the response to cytotoxic chemotherapeutic agents in breast cancer cells.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin-Like Growth Factor I,
http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, IGF Type 1,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen
|
pubmed:status |
MEDLINE
|
pubmed:issn |
1021-335X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
8
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
325-9
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:11182049-Antibodies, Monoclonal,
pubmed-meshheading:11182049-Breast Neoplasms,
pubmed-meshheading:11182049-Cell Division,
pubmed-meshheading:11182049-Cell Survival,
pubmed-meshheading:11182049-Doxorubicin,
pubmed-meshheading:11182049-Female,
pubmed-meshheading:11182049-Humans,
pubmed-meshheading:11182049-Insulin-Like Growth Factor I,
pubmed-meshheading:11182049-Paclitaxel,
pubmed-meshheading:11182049-Receptor, IGF Type 1,
pubmed-meshheading:11182049-Receptors, Estrogen,
pubmed-meshheading:11182049-Tumor Cells, Cultured
|
pubmed:articleTitle |
Insulin-like growth factor-I receptor antagonism results in increased cytotoxicity of breast cancer cells to doxorubicin and taxol.
|
pubmed:affiliation |
University of Tennessee-Memphis College of Medicine, Department of Surgery/Surgical Oncology, Memphis, TN 38163, USA. dbeech@utmem.edu
|
pubmed:publicationType |
Journal Article,
Comparative Study
|